Multicenter Blind Randomized Placebo-Controlled Study of a Live Recombinant Pertussis Vaccine «GamLPV»: Еvaluation of Safety and Tolerability
- 2 January 2026
- journal article
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 24 (6)
Abstract
Relevance . A key feature of the modern pertussis epidemic is the increasing incidence of the disease against the backdrop of years of mass vaccination: since the mid-1950s, with whole-cell pertussis vaccines (WCPV) as part of the DPT vaccine, and since the 1990s, with acellular pertussis vaccines (aPV) as part of the DTaP vaccine in many economically developed countries. The immune response that develops after whooping cough persists for up to 20 years, compared to 4 to 14 years after WCPV vaccination, and up to 6 years after APV vaccination. Aim . Assessment of the safety of the live recombinant pertussis vaccine «GamLPV» in a multicenter, blind, randomized, placebo-controlled study with double intranasal administration to adult volunteers. Materials and methods . The study involved 260 adult volunteers aged 18 to 65 years: 210 people in the study «GamLPV» group and 50 people in the «Placebo» group. The vaccine «GamLPV» was administered in a dose of 4.5 x 109 CFU intranasally twice with an interval in 60 ± 5 days, as well as the comparison drug (Placebo). Safety and tolerability were assessed based on data on the frequency of registration, nature and severity of adverse events (AEs) with a double intranasal drug administration of the vaccine. Results and discussion . During the study, no serious and severe AEs were registered. The analysis of the registered AEs did not confirm a reliable dependence on the administration of the GamLPV and, when compared with placebo, did not reveal statistically significant differences. We show that there was no statistically significant difference in safety parameters between the compared groups of volunteers who administered the GamLPV or placebo. The data from laboratory and instrumental examinations did not reveal significant deviations from the norm and the difference between the «GamLPV» and «Placebo» groups. Conclusions The results of the phase III of clinical trial vaccine in adult volunteers indicate good tolerability and a high safety profile of the GamLPV vaccine. Based on the conducted research, permission was obtained from the Ministry of Health of the Russian Federation for a new clinical trial of the GamLPV with the participation of volunteers aged 6 and 14 years.Keywords
This publication has 18 references indexed in Scilit:
- Global resurgence of pertussis: A perspective from ChinaJournal of Infection, 2024
- Repeated Bordetella pertussis Infections Are Required to Reprogram Acellular Pertussis Vaccine–Primed Host Responses in the Baboon ModelThe Journal of Infectious Diseases, 2023
- Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trialThe Lancet, 2023
- Global spatial dynamics and vaccine-induced fitness changes of Bordetella pertussisScience Translational Medicine, 2022
- Pertussis (Whooping Cough)The Journal of Infectious Diseases, 2021
- Bordetella pertussis in School-Age Children, Adolescents and Adults: A Systematic Review of Epidemiology and Mortality in EuropeInfectious Diseases and Therapy, 2021
- Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humansJournal of Clinical Investigation, 2020
- A Phase I Clinical Study of a Live Attenuated Bordetella pertussis Vaccine - BPZE1; A Single Centre, Double-Blind, Placebo-Controlled, Dose-Escalating Study of BPZE1 Given Intranasally to Healthy Adult Male VolunteersPLOS ONE, 2014
- Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate modelProceedings of the National Academy of Sciences, 2013
- Atypical Disease after Bordetella pertussis Respiratory Infection of Mice with Targeted Disruptions of Interferon-γ Receptor or Immunoglobulin μ Chain GenesJournal of Experimental Medicine, 1997